Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway

Molecules. 2016 Dec 21;21(12):1756. doi: 10.3390/molecules21121756.

Abstract

Specnuezhenide (SPN), one of the main ingredients of Chinese medicine "Nü-zhen-zi", has anti-angiogenic and vision improvement effects. However, studies of its effect on retinal neovascularization are limited so far. In the present study, we established a vascular endothelial growth factor A (VEGFA) secretion model of human acute retinal pigment epithelial-19 (ARPE-19) cells by exposure of 150 μM CoCl₂ to the cells and determined the VEGFA concentrations, the mRNA expressions of VEGFA, hypoxia inducible factor-1α (HIF-1α) & prolyl hydroxylases 2 (PHD-2), and the protein expressions of HIF-1α and PHD-2 after treatment of 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1, 1.0 μg/mL) or SPN (0.2, 1.0 and 5.0 μg/mL). Furthermore, rat pups with retinopathy were treated with SPN (5.0 and 10.0 mg/kg) in an 80% oxygen atmosphere and the retinal avascular areas were assessed through visualization using infusion of ADPase and H&E stains. The results showed that SPN inhibited VEGFA secretion by ARPE-19 cells under hypoxia condition, down-regulated the mRNA expressions of VEGFA and PHD-2 slightly, and the protein expressions of VEGFA, HIF-1α and PHD-2 significantly in vitro. SPN also prevented hypoxia-induced retinal neovascularization in a rat model of oxygen-induced retinopathy in vivo. These results indicate that SPN ameliorates retinal neovascularization through inhibition of HIF-1α/VEGF signaling pathway. Therefore, SPN has the potential to be developed as an agent for the prevention and treatment of diabetic retinopathy.

Keywords: angiogenesis; hypoxia-inducible factor-1; oxygen-induced retinopathy; specnuezhenide; vascular endothelial growth factor.

MeSH terms

  • Angiogenesis Inhibitors / isolation & purification
  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Cell Hypoxia
  • Cell Line
  • Cobalt / pharmacology
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / genetics
  • Diabetic Retinopathy / metabolism
  • Diabetic Retinopathy / pathology
  • Disease Models, Animal
  • Epithelial Cells / cytology
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Gene Expression Regulation
  • Glucosides / isolation & purification
  • Glucosides / pharmacology*
  • Humans
  • Hypoxia / complications
  • Hypoxia / drug therapy*
  • Hypoxia / genetics
  • Hypoxia / pathology
  • Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors*
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Hypoxia-Inducible Factor-Proline Dioxygenases / genetics
  • Hypoxia-Inducible Factor-Proline Dioxygenases / metabolism
  • Indazoles / pharmacology
  • Ligustrum / chemistry*
  • Plant Extracts / chemistry
  • Pyrans / isolation & purification
  • Pyrans / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Retinal Neovascularization / drug therapy*
  • Retinal Neovascularization / etiology
  • Retinal Neovascularization / genetics
  • Retinal Neovascularization / pathology
  • Retinal Pigment Epithelium / cytology
  • Retinal Pigment Epithelium / drug effects
  • Retinal Pigment Epithelium / metabolism
  • Signal Transduction
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Glucosides
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Indazoles
  • Plant Extracts
  • Pyrans
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
  • nuezhenide
  • Cobalt
  • EGLN1 protein, human
  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • cobaltous chloride